Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals, has entered into a definitive merger agreement to be acquired by an affiliate of private investment company TPG in a transaction with an equity value of $1.9 billion. 17 July 2012
Generics
USA-based CritiTech and privately-held Indian group Finoso Pharma have formally established a joint venture which will be named Finotech Pharma with a business office in Lawrence, Kansas, USA. 16 July 2012
Generics
Agila Specialties Pharma Canada, which is part of the injectable drug division of Indian generic drugmaker Strides Arcolab (BO: 532531), has formed a joint venture with Jamp Pharma, a Canadian generic drug company, to introduce a variety of injectable generic drugs in Canada. 16 July 2012
Generics
UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New Drug Application to the US Food and Drug Administration for Tykerb (lapatinib) in combination with trastuzumab (Roche's Herceptin) for the treatment of patients with HER2 (ErbB2)-positive metastatic breast cancer who have received prior trastuzumab therapy. 13 July 2012
Generics
US drugs giant Merck & Co has begun talks with privately-held Indian drugmaker Micro Labs to acquire the maker of active pharmaceutical ingredients (APIs) and finished formulation, accord to a report by the local Financial Express. 22 June 2012
Generics
US pharma major Eli Lilly (NYSE: LLY) says it will increase of its network of manufacturing capabilities in the key emerging market of China through an expanded collaboration with Novast Laboratories, a generic and specialty pharmaceutical company based in Nantong, China, which has established high-quality systems and manufacturing facilities for the global and domestic Chinese markets. 13 June 2012
Generics
Belgium's leading pharma company UCB (Euronext Brussels: UCB) says it has signed an agreement to acquire a 51% stake in Meizler Biopharma, a privately-owned Brazilian drugmaker, creating Meizler UCB Biopharma SA. 31 May 2012
Generics
Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, revealed this morning that it has entered into an agreeement to acquire the Brazilian compony Multilab Industria e Comercio de Produtos Farmaceuticos through its wholly-owned subsidiary Takeda Farmaceutica Brasil. 25 May 2012
Generics
Privately-held US aesthetics company Suneva Medical has acquired an aesthetic product portfolio from Spear Pharmaceuticals. Under the terms of the agreement, Suneva will acquire worldwide rights to Refissa and its marketed generic equivalent. 24 May 2012
Generics
Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its franchise with a definitive agreement to acquire Melville, New York, USA-based private equity-owned, specialty dermatology generics company Fougera Pharmaceuticals for $1.525 billion in an all-cash transaction. 3 May 2012
Generics
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's largest generics companies, said yesterday that it has settled patent infringement litigation regarding US Patent Number 7,132,570 with respect to US rival Mylan's (Nasdaq: MYL) Abbreviated New Drug Application for Teva's wakefulness product Nuvigil (armodafinil) tablets. 1 May 2012
Generics
The economic recession has been a double-edged sword for the international generic drugs business. Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored. 29 April 2012
Generics
US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings, including the 'BBB' Issuer Default Rating (IDR), on Rating Watch Negative as a result of its proposed acquisition of generics rival the privately held Actavis (The Pharma Letter April 26). The ratings apply to approximately $1.1 billion in debt outstanding as of Dec. 31, 2011. 26 April 2012
Generics
As has been widely rumoured over this week, Watson Pharmaceuticals (NYSE: WPI) has confirmed a definitive agreement to acquire privately-owned generics firm Actavis, formerly an Icelandic group but now headquartered in Switzerland, for an upfront payment of 4.25 billion euros ($5.61 billion),. As a result of this acquisition, Watson will become the third largest global generics company with 2012 anticipated pro forma revenue of around $8 billion. 26 April 2012
Generics
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico with a broad product portfolio, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for around $71 million. 19 April 2012
Generics
USA-headquartered Sigma-Aldrich (Nasdaq: SIAL) has acquired all outstanding shares of Cleveland, Ohio-based, Research Organics to expand the company's buffer production capacity and to increase its portfolio of PharmaGrade raw materials for the biopharmaceutical and diagnostic markets. Terms of the purchase, which is expected to be neutral to 2012 earnings per share, were not disclosed. 16 April 2012
Generics
Icelandic generic drugmaker Actavis is said to be in talks to be acquired by US peer Watson Pharmaceuticals (NYSE: WPI) for as much as 5.5 billion euros ($7.3 billion), according to a Reuters report, citing a person with knowledge of the matter. 22 March 2012
Generics
Lyon, France-based drug delivery firm Flamel Technologies (Nasdaq: FLML) said last week that it has acquired Eclat Pharmaceuticals, a US specialty pharmaceutical company that is focused on the development, approval, and commercialization of niche brands and generic products. 19 March 2012
Generics
The Canadian subsidiary of US generic drugmaker Mylan (Nasdaq: MYL) has received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg, a generic version of cholesterol lowerer Crestor from Anglo-Swedish drug major AstraZeneca. 18 March 2012
Generics
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an agreement to buy certain assets from Gerot Lannach, a branded generics pharmaceutical company based in Austria. 14 March 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze